Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Adial Pharmaceuticals ( (ADIL) ) has shared an announcement.
Adial Pharmaceuticals has extended its CEO Cary Claiborne’s tenure with a new three-year employment agreement effective from December 5, 2024. The revised terms include a higher bonus target, set at 50% of Claiborne’s base salary contingent on meeting specific objectives, and stock options for 350,000 shares under the company’s equity plan, vesting over 36 months.
See more insights into ADIL stock on TipRanks’ Stock Analysis page.
